COVID-19: the use of immunotherapy in metastatic lung cancer
Type
ArticleAbstract
Significant gains have been made in lung cancer morbidity and mortality since the introduction of PD-1 therapy. These benefits still exist in the ongoing COVID-19 pandemic, however, ongoing treatment may place a subset of patients at increased riskSignificant gains have been made in lung cancer morbidity and mortality since the introduction of PD-1 therapy. These benefits still exist in the ongoing COVID-19 pandemic, however, ongoing treatment may place a subset of patients at increased risk
See less
See less
Date
2020Funding information
Takeda (United States)
Amgen (United States)
Boehringer Ingelheim (United States)
Bristol-Myers Squibb (United States)
MSD (United States)
Pfizer (United Kingdom)
Roche (United States)
AstraZeneca (United Kingdom)
Licence
OtherFaculty/School
Faculty of Medicine and Health, Sydney Medical SchoolShare